Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03394365

Title field or adapter rule

{'original_value': 'Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:23.113688+00:00

Published At

2026-10-19T00:00:00+00:00

Record Updated At

2026-10-19

Source Retrieved At

2026-10-31T22:17:52.415050+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)", "Solid Organ Transplant Complications", "Lymphoproliferative Disorders", "Allogeneic Hematopoietic Cell Transplant", "Stem Cell Transplant Complications"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-19", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03394365"

protocolSection.identificationModule.officialTitle

"Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) (protocolSection.conditionsModule.conditions)
• Solid Organ Transplant Complications (protocolSection.conditionsModule.conditions)
• Lymphoproliferative Disorders (protocolSection.conditionsModule.conditions)
• Allogeneic Hematopoietic Cell Transplant (protocolSection.conditionsModule.conditions)
• Stem Cell Transplant Complications (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Cohort HCT (C-HCT)', 'Cohort SOT-R (C-SOT-R)', 'Cohort SOT-R+C (C-SOT-R+C)'], 'description': 'Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.', 'name': 'tabelecleucel', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.